Evidence map›Paper›PMID 24165885›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia.

Jennifer A Hadley, Rodolphe Nenert, Nina V Kraguljac, Mark S Bolding, David M White, Frank M Skidmore, Kristina M Visscher, Adrienne C Lahti

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jennifer A HadleyDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Rodolphe NenertDepartment of Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Nina V KraguljacDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Mark S BoldingDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
David M WhiteDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Frank M SkidmoreDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kristina M VisscherDepartment of Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Adrienne C LahtiDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAWRENCE C SINCICH · 1985 to 2026
$16.9M
UAB Center for Clinical and Translational Science (CCTS) UL1UL1TR000165 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$9.6M
Treatment response in schizophrenia: bridging imaging and postmortem studiesR01MH081014 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2009 to 2013
$1.8M
NCATS NIH HHS UL1TR000165NEI NIH HHS P30EY003039NIA NIH HHS 2P30AG022838NIGMS NIH HHS 5T32GM008361NIMH NIH HHS R01 MH081014NIMH NIH HHS R01MH081014
6 · The paper itself

Abstract

Medication management in schizophrenia is a lengthy process, as the lack of clinical response can only be confirmed after at least 4 weeks of antipsychotic treatment at a therapeutic dose. Thus, there is a clear need for the discovery of biomarkers that have the potential to accelerate the management of treatment. Using resting-state functional MRI, we examined the functional connectivity of the ventral tegmental area (VTA), the origin of the mesocorticolimbic dopamine projections, in 21 healthy controls and 21 unmedicated patients with schizophrenia at baseline (pre-treatment) and after 1 week of treatment with the antipsychotic drug risperidone (1-week post-treatment). Group-level functional connectivity maps were obtained and group differences in connectivity were assessed on the groups' participant-level functional connectivity maps. We also examined the relationship between pre-treatment/1-week post-treatment functional connectivity and treatment response. Compared with controls, patients exhibited significantly reduced pre-treatment VTA/midbrain connectivity to multiple cortical and subcortical regions, including the dorsal anterior cingulate cortex (dACC) and thalamus. After 1 week of treatment, VTA/midbrain connectivity to bilateral regions of the thalamus was re-established. Pre-treatment VTA/midbrain connectivity strength to dACC was positively correlated with good response to a 6-week course of risperidone, whereas pre-treatment VTA/midbrain connectivity strength to the default mode network was negatively correlated. Our findings suggest that VTA/midbrain resting-state connectivity may be a useful biomarker for the prediction of treatment response.

Indexed as

Brain MappingAdultAnalysis of VarianceAntipsychotic AgentsFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysOxygenPsychiatric Status Rating ScalesRisperidoneSchizophreniaAntipsychotic AgentsOxygenRisperidone

Identifiers

PMID24165885
PMCPMC3924537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.